Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
暂无分享,去创建一个
Cheng Cheng | Elaine Coustan-Smith | Dario Campana | Ching-Hon Pui | Deqing Pei | J. Downing | Cheng Cheng | D. Campana | C. Pui | Guangchun Song | E. Coustan-Smith | D. Pei | C. Flotho | Guangchun Song | James R Downing | Christian Flotho | Shotaro Iwamoto | S. Iwamoto | Deqing Pei
[1] J. Downing,et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.
[2] F. Behm,et al. Immunophenotyping of leukemia. , 2000, Journal of immunological methods.
[3] F. Behm,et al. Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. , 2001, Blood.
[4] Ching-Hon Pui,et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. , 2005, Blood.
[5] Cheng Cheng,et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.
[6] M. Relling,et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.
[7] J. Downing,et al. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Sakamaki,et al. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis , 1999, Nature.
[9] H. Yoo,et al. Role of FLASH in caspase-8-mediated activation of NF-kappaB: dominant-negative function of FLASH mutant in NF-kappaB signaling pathway. , 2005, Oncogene.
[10] Cheng Cheng,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.
[11] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[12] F. Behm,et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. , 1999, Blood.
[13] Cheng Cheng,et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. , 2006, Blood.
[14] F. Behm,et al. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. , 1992, Blood.
[15] J. Downing,et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.
[16] D. Campana,et al. Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.
[17] A. Órfão,et al. Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.
[18] D. Campana,et al. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.
[19] H. Yoo,et al. Role of FLASH in caspase-8-mediated activation of NF-κB: dominant-negative function of FLASH mutant in NF-κB signaling pathway , 2005, Oncogene.
[20] Thomas Flohr,et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.
[21] D. Hogg,et al. Cell cycle dependent regulation of the protein kinase TTK. , 1994, Oncogene.
[22] R. Gentleman,et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. , 2004, Blood.
[23] W. Hop,et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.
[24] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[25] F. Behm,et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.
[26] Lucila Ohno-Machado,et al. Analysis of matched mRNA measurements from two different microarray technologies , 2002, Bioinform..
[27] S. Sallan,et al. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment , 2003, Current opinion in hematology.
[28] L. Frankel,et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Elaine Coustan-Smith,et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.
[30] D. Campana,et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. , 2002, Blood.
[31] G. Chrousos,et al. Tumor Necrosis Factor α Receptor- and Fas-associated FLASH Inhibit Transcriptional Activity of the Glucocorticoid Receptor by Binding to and Interfering with Its Interaction with p160 Type Nuclear Receptor Coactivators* , 2003, The Journal of Biological Chemistry.
[32] H. Cavé,et al. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .
[33] W. Hiddemann,et al. Correlation of protein expression and gene expression in acute leukemia , 2003, Cytometry. Part B, Clinical cytometry.
[34] F. Behm,et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. , 1996, The Journal of clinical investigation.
[35] F. Behm,et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.
[36] Hall,et al. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA , 1997, British journal of haematology.
[37] Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .
[38] D. Campana,et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.
[39] D. Campana,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.
[40] W. Williams,et al. A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia , 1998, Leukemia.
[41] J. Downing,et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.
[42] C. Pui,et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements , 2003, Leukemia.
[43] Ching-Hon Pui,et al. Acute lymphoblastic leukemia. , 2004, The New England journal of medicine.
[44] H. Gronemeyer,et al. DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells--toward a basis for the opposite actions elicited by two nuclear receptors? , 2004, Molecular pharmacology.
[45] D. Campana. Determination of minimal residual disease in leukaemia patients , 2003, British journal of haematology.
[46] S. Raimondi,et al. Cytogenetics as a Diagnostic Aid for Childhood Hematologic Disorders , 1998 .
[47] Pui,et al. Childhood Acute Lymphoblastic Leukemia. , 1997, The oncologist.
[48] Cheng Cheng,et al. Statistical Significance Threshold Criteria For Analysis of Microarray Gene Expression Data , 2004, Statistical applications in genetics and molecular biology.
[49] H. Gadner,et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.